In addition, when compared, the high to low securin immunopositivity risk for breast cancer death was 2.7-fold for patients with small and 3.6-fold for patients with large tumour size (P=0.042, 95% CI 1.0–7.0 and P=0.046, 95% CI 1.0–12.4, respectively). This evidence concerns the gene PTTG1 and neoplasm.